Recent Updates on Multiple Myeloma [Working Title]
Over the past two decades, treatment of multiple myeloma (MM) has advanced dramatically. However,... more Over the past two decades, treatment of multiple myeloma (MM) has advanced dramatically. However, despite the introduction of several lines of novel therapeutics, autologous hematopoietic stem cell transplantation (HSCT) followed by maintenance therapy is the current standard of care in transplant eligible patients. Autologous HSCT can be performed with or without cryopreservation with equivalent short-term and long-term outcomes. In patients with MM, performance of autologous HSCT at outpatient setting is safe, feasible and has a number of advantages such as saving hospital beds and reducing treatment costs. Autologous HSCT can be safely performed in patients with MM having renal dysfunction or failure although particular attention should be made to the timing of administering medications and stem cells with respect to hemodialysis and dose reduction of specific medications according to creatinine clearance. Tandem autologous HSCT is of value in younger patients with adverse cytoge...
Recent Updates on Multiple Myeloma [Working Title]
Autologous hematopoietic stem cell transplantation is still the standard of care in patients with... more Autologous hematopoietic stem cell transplantation is still the standard of care in patients with multiple myeloma who are eligible for transplantation, despite the recent availability of several lines of novel therapies. Several studies have shown that autologous transplantation using non-cryopreserved stem cells is safe, cost-effective, and leads to outcomes that are equivalent to transplantation of cryopreserved autologous stem cells. With daily clinical evaluation and intensive supportive care, performance of autologous stem cell transplantation at outpatient setting is safe, feasible, and cost-effective. However, there are specific inclusion and exclusion criteria that should be taken into consideration to select the right candidates for this modality of transplantation. Recipients of outpatient transplantation may require hospitalization in case of certain complications, such as febrile neutropenia, sepsis, decrease in performance status, and severe mucositis. Following outpat...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided t... more License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation is considered the standard of care for multiple myeloma patients who are eligible for transplantation. The process of autografting comprises the following steps: control of the primary disease by using a certain induction therapeutic protocol, mobilization of stem cells, collection of mobilized stem cells by apheresis, cryopreservation of the apheresis product, administration of high-dose pretransplant conditioning therapy, and finally infusion of the cryopreserved stem cells after thawing. However, in cancer centers that treat patients with multiple myeloma and have transplantation capabilities but lack or are in the process of acquiring cryopreservation facilities, alternatively noncryopreserved autologous stem cell therapy has been performed with remarkable success...
Mesenchymal Stem Cells (MSCs); which were first described by Alexander Fridenstein in the 1960s; ... more Mesenchymal Stem Cells (MSCs); which were first described by Alexander Fridenstein in the 1960s; are heterogeneous, non-hematopoietic, adult multipotent stromal progenitor cells that are capable of self-renewal and differentiation into various cell types [1-8]. They can be isolated from various sources including: Bone Marrow (BM) which is the main source, peripheral blood, umbilical cord blood, amniotic fluid, placenta, Adipose Tissue (AT), dental pulp, synovial fluid, salivary glands, liver, lung, skin and skeletal muscles [1-10]. MSCs have the following distinguishing features: adherence to the plastic vessel; capacity to different into osteoblasts, adipocytes and chondrocytes; and being characteristically positive for CD105, CD73, and CD90 and characteristically negative for CD45, CD34, CD11b, CD14, CD19, CD79a, and human leukocyte antigen (HLA)-DR on flow cytometry [1,3,4,11-16]. However, under certain circumstances, MSCs obtained from BM, AT, and other sources may express CD34 ...
Enterococci commonly found in the intestinal flora have emerged as common nosocomial pathogens. U... more Enterococci commonly found in the intestinal flora have emerged as common nosocomial pathogens. Up till 1988, all enterococcal strains were sensitive to vancomycin. However, there are now reports of vancomycin resistant Enterococcus (VRE) from Europe and USA. In this communication we report the case of a patient with acute myeloid leukaemia who was colonized with VRE and subsequently developed septicaemia. The enterococci were resistant to both vancomycin and teicoplanin but sensitive to tetracycline and trimethoprim. The patient made a favourable response to tetracycline therapy. It is suggested that all enterococcal isolates should be routinely screened for vancomycin resistance, especially in immunocomprnmised patients on prophylactic antibiotics
Journal of Regenerative Medicine & Biology Research, 2020
Systemic sclerosis systemic is a systemic autoimmune disease that ultimately leads to severe dama... more Systemic sclerosis systemic is a systemic autoimmune disease that ultimately leads to severe damage and failure of multiple body organs. The disease is associated with significant morbidity and mortality as well as poor response to the available immunosuppressive therapies. Stem cells particularly hematopoietic and mesenchymal stem cells have recently been shown to be not only safe but also efficacious in the treatment of patients with systemic sclerosis. Autologous transplantation of hematopoietic stem cells has become the standard of care for patients with severe systemic sclerosis. Mesenchymal stem cells, alone or in combination with other therapies, have been shown to be effective in the treatment of certain forms and complications of systemic sclerosis such as chronic sclerodermatous graft versus host disease. The review will discuss the various aspects of systemic sclerosis and it will highlight the role of hematopoietic as well as mesenchymal stem cells in the treatment of sy...
Journal of Regenerative Medicine & Biology Research, 2020
Mesenchymal Stem Cells (MSCs); which were first described by Alexander Fridenstein in the 1960s; ... more Mesenchymal Stem Cells (MSCs); which were first described by Alexander Fridenstein in the 1960s; are heterogeneous, non-hematopoietic, adult multipotent stromal progenitor cells that are capable of self-renewal and differentiation into various cell types [1-8]. They can be isolated from various sources including: Bone Marrow (BM) which is the main source, peripheral blood, umbilical cord blood, amniotic fluid, placenta, Adipose Tissue (AT), dental pulp, synovial fluid, salivary glands, liver, lung, skin and skeletal muscles [1-10]. MSCs have the following distinguishing features: adherence to the plastic vessel; capacity to different into osteoblasts, adipocytes and chondrocytes; and being characteristically positive for CD105, CD73, and CD90 and characteristically negative for CD45, CD34, CD11b, CD14, CD19, CD79a, and human leukocyte antigen (HLA)-DR on flow cytometry [1,3,4,11-16]. However, under certain circumstances, MSCs obtained from BM, AT, and other sources may express CD34 ...
Recent Updates on Multiple Myeloma [Working Title]
Over the past two decades, treatment of multiple myeloma (MM) has advanced dramatically. However,... more Over the past two decades, treatment of multiple myeloma (MM) has advanced dramatically. However, despite the introduction of several lines of novel therapeutics, autologous hematopoietic stem cell transplantation (HSCT) followed by maintenance therapy is the current standard of care in transplant eligible patients. Autologous HSCT can be performed with or without cryopreservation with equivalent short-term and long-term outcomes. In patients with MM, performance of autologous HSCT at outpatient setting is safe, feasible and has a number of advantages such as saving hospital beds and reducing treatment costs. Autologous HSCT can be safely performed in patients with MM having renal dysfunction or failure although particular attention should be made to the timing of administering medications and stem cells with respect to hemodialysis and dose reduction of specific medications according to creatinine clearance. Tandem autologous HSCT is of value in younger patients with adverse cytoge...
Recent Updates on Multiple Myeloma [Working Title]
Autologous hematopoietic stem cell transplantation is still the standard of care in patients with... more Autologous hematopoietic stem cell transplantation is still the standard of care in patients with multiple myeloma who are eligible for transplantation, despite the recent availability of several lines of novel therapies. Several studies have shown that autologous transplantation using non-cryopreserved stem cells is safe, cost-effective, and leads to outcomes that are equivalent to transplantation of cryopreserved autologous stem cells. With daily clinical evaluation and intensive supportive care, performance of autologous stem cell transplantation at outpatient setting is safe, feasible, and cost-effective. However, there are specific inclusion and exclusion criteria that should be taken into consideration to select the right candidates for this modality of transplantation. Recipients of outpatient transplantation may require hospitalization in case of certain complications, such as febrile neutropenia, sepsis, decrease in performance status, and severe mucositis. Following outpat...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided t... more License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation is considered the standard of care for multiple myeloma patients who are eligible for transplantation. The process of autografting comprises the following steps: control of the primary disease by using a certain induction therapeutic protocol, mobilization of stem cells, collection of mobilized stem cells by apheresis, cryopreservation of the apheresis product, administration of high-dose pretransplant conditioning therapy, and finally infusion of the cryopreserved stem cells after thawing. However, in cancer centers that treat patients with multiple myeloma and have transplantation capabilities but lack or are in the process of acquiring cryopreservation facilities, alternatively noncryopreserved autologous stem cell therapy has been performed with remarkable success...
Mesenchymal Stem Cells (MSCs); which were first described by Alexander Fridenstein in the 1960s; ... more Mesenchymal Stem Cells (MSCs); which were first described by Alexander Fridenstein in the 1960s; are heterogeneous, non-hematopoietic, adult multipotent stromal progenitor cells that are capable of self-renewal and differentiation into various cell types [1-8]. They can be isolated from various sources including: Bone Marrow (BM) which is the main source, peripheral blood, umbilical cord blood, amniotic fluid, placenta, Adipose Tissue (AT), dental pulp, synovial fluid, salivary glands, liver, lung, skin and skeletal muscles [1-10]. MSCs have the following distinguishing features: adherence to the plastic vessel; capacity to different into osteoblasts, adipocytes and chondrocytes; and being characteristically positive for CD105, CD73, and CD90 and characteristically negative for CD45, CD34, CD11b, CD14, CD19, CD79a, and human leukocyte antigen (HLA)-DR on flow cytometry [1,3,4,11-16]. However, under certain circumstances, MSCs obtained from BM, AT, and other sources may express CD34 ...
Enterococci commonly found in the intestinal flora have emerged as common nosocomial pathogens. U... more Enterococci commonly found in the intestinal flora have emerged as common nosocomial pathogens. Up till 1988, all enterococcal strains were sensitive to vancomycin. However, there are now reports of vancomycin resistant Enterococcus (VRE) from Europe and USA. In this communication we report the case of a patient with acute myeloid leukaemia who was colonized with VRE and subsequently developed septicaemia. The enterococci were resistant to both vancomycin and teicoplanin but sensitive to tetracycline and trimethoprim. The patient made a favourable response to tetracycline therapy. It is suggested that all enterococcal isolates should be routinely screened for vancomycin resistance, especially in immunocomprnmised patients on prophylactic antibiotics
Journal of Regenerative Medicine & Biology Research, 2020
Systemic sclerosis systemic is a systemic autoimmune disease that ultimately leads to severe dama... more Systemic sclerosis systemic is a systemic autoimmune disease that ultimately leads to severe damage and failure of multiple body organs. The disease is associated with significant morbidity and mortality as well as poor response to the available immunosuppressive therapies. Stem cells particularly hematopoietic and mesenchymal stem cells have recently been shown to be not only safe but also efficacious in the treatment of patients with systemic sclerosis. Autologous transplantation of hematopoietic stem cells has become the standard of care for patients with severe systemic sclerosis. Mesenchymal stem cells, alone or in combination with other therapies, have been shown to be effective in the treatment of certain forms and complications of systemic sclerosis such as chronic sclerodermatous graft versus host disease. The review will discuss the various aspects of systemic sclerosis and it will highlight the role of hematopoietic as well as mesenchymal stem cells in the treatment of sy...
Journal of Regenerative Medicine & Biology Research, 2020
Mesenchymal Stem Cells (MSCs); which were first described by Alexander Fridenstein in the 1960s; ... more Mesenchymal Stem Cells (MSCs); which were first described by Alexander Fridenstein in the 1960s; are heterogeneous, non-hematopoietic, adult multipotent stromal progenitor cells that are capable of self-renewal and differentiation into various cell types [1-8]. They can be isolated from various sources including: Bone Marrow (BM) which is the main source, peripheral blood, umbilical cord blood, amniotic fluid, placenta, Adipose Tissue (AT), dental pulp, synovial fluid, salivary glands, liver, lung, skin and skeletal muscles [1-10]. MSCs have the following distinguishing features: adherence to the plastic vessel; capacity to different into osteoblasts, adipocytes and chondrocytes; and being characteristically positive for CD105, CD73, and CD90 and characteristically negative for CD45, CD34, CD11b, CD14, CD19, CD79a, and human leukocyte antigen (HLA)-DR on flow cytometry [1,3,4,11-16]. However, under certain circumstances, MSCs obtained from BM, AT, and other sources may express CD34 ...
Uploads
Papers by Khalid Al-Anazi